Patents Assigned to LIPOTEK PTY LTD.
-
Patent number: 10507236Abstract: The present invention is directed generally to chimeric proteins that can facilitate targeting of nanoparticulate carriers to antigen presenting cells, and to nanoparticulate carriers comprising these chimeric proteins. The invention is also directed to methods of internalizing an antigen in an antigen presenting cell, and methods of eliciting an immune response to an antigen in a subject, using the nanoparticulate carriers comprising the chimeric proteins.Type: GrantFiled: October 9, 2015Date of Patent: December 17, 2019Assignees: Lipotek Pty Ltd, The Australian National UniversityInventors: Jason David Price, Christopher Parish, Ines Atmosukarto
-
Publication number: 20140341971Abstract: The present invention relates to a composition for targeting dendritic cells. In particular, the present invention relates to a composition comprising: a) one or more antigens; b) an anti-DC-SIGN immunoglobulin single variable domain; and c) a carrier which carries a) and b). The invention further relates to formulations, compositions and devices comprising such anti-DC-SIGN molecules and their use as a medicament and in the treatment of cancer, suitably melanoma.Type: ApplicationFiled: June 20, 2014Publication date: November 20, 2014Applicants: LIPOTEK PTY LTD, DOMANTIS LIMITEDInventors: Joseph ALTIN, Ines Atmosukarto, Rudolf Maria De Wildt, Christopher Parish, Jason Price
-
Patent number: 8779107Abstract: The present disclosure relates to a composition for targeting dendritic cells. In particular, the present disclosure relates to a composition comprising: a) one or more antigens; b) an anti-DC-SIGN immunoglobulin single variable domain; and c) a carrier which carries a) and b). The disclosure further relates to formulations, compositions and devices comprising such anti-DC-SIGN molecules and their use as a medicament and in the treatment of cancer, suitably melanoma.Type: GrantFiled: October 19, 2009Date of Patent: July 15, 2014Assignees: Lipotek Pty Ltd, Domantis LimitedInventors: Joseph Altin, Ines Atmosukarto, Rudolf Maria De Wildt, Christopher Parish, Jason Price
-
Publication number: 20140079728Abstract: The present invention provides an adjuvanting material, the adjuvanting material comprising a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group. Further, the present invention provides an immunogenic composition comprising (a) a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group; (b) an antigen comprising a metal affinity tag; and optionally (c) metal ions, whereby the antigen is linked to the lipid dendritic cell targeting moiety via the interaction between the metal affinity tag and the metal chelating group.Type: ApplicationFiled: September 11, 2013Publication date: March 20, 2014Applicant: Lipotek Pty Ltd.Inventors: David C. Jackson, Christopher R. Parish
-
Publication number: 20130142864Abstract: The invention provides a composition for modulating immunity by the in vivo targeting of an antigen to dendritic cells. The composition comprises: a preparation of antigen-containing membrane vesicles or antigen-containing liposomes which have on their surfaces a plurality of metal chelating groups; and, a ligand for a receptor on the dendritic cells, the ligand being linked to a metal chelating group via a metal affinity tag on the ligand. The composition further includes an immunomodulatory factor. A process for preparing the composition is also provided. The invention further provides a method of modulating an immune disorder, and methods of treating tumours and infections.Type: ApplicationFiled: December 28, 2012Publication date: June 6, 2013Applicant: Lipotek Pty Ltd.Inventors: Joseph Altin, Christopher Richard Parish
-
Publication number: 20110200632Abstract: The present invention provides an adjuvanting material, the adjuvanting material comprising a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group. Further, the present invention provides an immunogenic composition comprising (a) a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group; (b) an antigen comprising a metal affinity tag; and optionally (c) metal ions, whereby the antigen is linked to the lipid dendritic cell targeting moiety via the interaction between the metal affinity tag and the metal chelating group.Type: ApplicationFiled: February 2, 2011Publication date: August 18, 2011Applicant: Lipotek Pty Ltd.Inventors: David C. Jackson, Christopher R. Parish
-
Publication number: 20080233143Abstract: The present invention provides an adjuvanting material, the adjuvanting material comprising a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group. Further, the present invention provides an immunogenic composition comprising (a) a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group; (b) an antigen comprising a metal affinity tag; and optionally (c) metal ions, whereby the antigen is linked to the lipid dendritic cell targeting moiety via the interaction between the metal affinity tag and the metal chelating group.Type: ApplicationFiled: February 7, 2006Publication date: September 25, 2008Applicant: LIPOTEK PTY LTD.Inventors: David C. Jackson, Christopher Richard Parish
-
Publication number: 20070026057Abstract: The invention provides a composition for modulating immunity by the in vivo targeting of an antigen to dendritic cells. The composition comprises: a preparation of antigen-containing membrane vesicles or antigen-containing liposomes which have on their surfaces a plurality of metal chelating groups; and, a ligand for a receptor on the dendritic cells, the ligand being linked to a metal chelating group via a metal affinity tag on the ligand. The composition further includes an immunomodulatory factor. A process for preparing the composition is also provided. The invention further provides a method of modulating an immune disorder, and methods of treating tumours and infections.Type: ApplicationFiled: August 23, 2004Publication date: February 1, 2007Applicant: LIPOTEK PTY LTD.Inventors: Joseph Altin, Christopher Parish